5'-Guanylic acid-¹³C₁₀,¹⁵N₅ dilithium  (Synonyms: 5'-GMP-¹³C₁₀,¹⁵N₅ dilithium; 5'-guanosine monophosphate-¹³C₁₀,¹⁵N₅ dilithium)

5'-Guanylic acid-¹³C₁₀,¹⁵N₅ (5'-GMP-¹³C₁₀,¹⁵N₅ dilithium; 5'-guanosine monophosphate-¹³C₁₀,¹⁵N₅) dilithium is ¹³C and ¹⁵N-labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

389.98

¹³C₁₀H₁₂Li₂¹⁵N₅O₈P

2483830-56-2

85-32-5

O=P(O[Li])(O[Li])O[13CH2][13C@H]1O[13C@@H]([15N]2[13C]([15N]=[13C]([15NH2])[15NH][13C]3=O)=[13C]3[15N]=[13CH]2)[13C@H](O)[13C@@H]1O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  [Content Brief]